Importantly, conformational epitope engineering is suitable for the development of vaccines against a broad spectrum of pathogenic protein structures and amyloids, such as amyloid beta and tau in Alzheimer’s disease, islet amyloid polypeptide (IAPP) in type II diabetes and others causing protein misfolding diseases. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.